Answers are grounded in this paper and cite their sources.
Retrospective study examines virological effectiveness and renal safety of TAF in chronic kidney disease patients, suggesting it is a viable option.
Long-term nucleos(t)ide analog (NUC) therapy is essential for chronic hepatitis B (CHB) management. However, data on long-term outcomes, particularly for patients switching to tenofovir alafenamide (TAF) and patients with chronic kidney disease (CKD), remain limited. This study aimed to evaluate the 5-year virological effectiveness and renal safety of sequential TAF therapy, with a focus on those with pre-existing CKD. This real-world, multicenter, retrospective study included 414 CHB patients aged ≥ 18 years who switched from a prior NUC to TAF and were followed for at least 5 years. Patients were stratified based on renal function (CKD or non-CKD) at baseline. Study endpoints included 5-year virological efficacy, biochemical and fibrosis responses, and renal function changes. Among the patients, 100 (24.2%) had CKD at the time of switching to TAF. Over 5 years, HBV DNA suppression rate increased from 85.0% to 100%, HBV DNA suppression with target not detected rate rose from 74.0% to 91.0%, and alanine aminotransferase normalization rate (AASLD criteria) improved from 66.0% to 79.0%, similar to the results of patients with non-CKD. Estimated glomerular filtration rate remained stable regardless of baseline renal status or prior NUC regimen, demonstrating long-term renal safety. There were no cases of HBV DNA breakthrough, including among those previously on combination NUCs. For patients with cirrhosis, the FIB-4 index significantly improved over time (p = 0.008). Sequential TAF therapy demonstrated robust virological efficacy, biochemical and fibrosis improvements, and excellent renal safety over 5 years, irrespective of baseline renal function.
No takes yet. Share an insight, caveat, or question.
Ogawa et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: